90 related articles for article (PubMed ID: 33015987)
21. On the Relevance of Soft Tissue Sarcomas Metabolic Landscape Mapping.
Esperança-Martins M; F Duarte I; Rodrigues M; Soares do Brito J; López-Presa D; Costa L; Fernandes I; Dias S
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232732
[TBL] [Abstract][Full Text] [Related]
22. Serum protein acidic and rich in cysteine (SPARC) as a prognostic marker in soft tissue sarcomas.
Morgan SS; Nagle RB; Cranmer LD
Clin Sarcoma Res; 2014 Jan; 4(1):2. PubMed ID: 24484617
[TBL] [Abstract][Full Text] [Related]
23. Progressive Improvement in 5-Year Survival Rates for Extremity Soft Tissue Sarcomas from 1999 to 2019.
Zastrow RK; El Sayed M; LiBrizzi CL; Jacobs AJ; Levin AS
Sarcoma; 2024; 2024():8880609. PubMed ID: 38410124
[TBL] [Abstract][Full Text] [Related]
24. Trends in the use of immunotherapy to treat soft tissue sarcoma.
Iwai Y; Baldwin XL; Feeney T; Agala CB; Yanagihara TK; Stein JN; Kim HJ; Spanheimer PM
Am J Surg; 2024 Jun; ():115794. PubMed ID: 38879356
[TBL] [Abstract][Full Text] [Related]
25. A Population-Based Long-Term Follow-Up of Soft Tissue Angiosarcomas: Characteristics, Treatment Outcomes, and Prognostic Factors.
Holm CE; Ørholt M; Talman ML; Abebe K; Thorn A; Baad-Hansen T; Petersen MM
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791913
[TBL] [Abstract][Full Text] [Related]
26. Ki-67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas, respectively.
Campos M; DE Campos SG; Ribeiro GG; Eguchi FC; Silva SR; DE Oliveira CZ; DA Costa AM; Curcelli EC; Nunes MC; Penna V; Longatto-Filho A
Oncol Lett; 2013 May; 5(5):1527-1535. PubMed ID: 23759874
[TBL] [Abstract][Full Text] [Related]
27. Follow-Up after Curative Surgical Treatment of Soft-Tissue Sarcoma for Early Detection of Recurrence: Which Patients Have More or Fewer Visits than Advised in Guidelines?
Kruiswijk AA; Kuhrij LS; Dorleijn DMJ; van de Sande MAJ; van Bodegom-Vos L; Marang-van de Mheen PJ
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760585
[TBL] [Abstract][Full Text] [Related]
28. Indicators of clinical performance in monitoring soft tissue sarcoma management: a population-based perspective.
Rugge M; Buja A; Tropea S; Girardi G; Cozzolino C; Zorzi M; Vecchiato A; Stefano A; Del Fiore P; Brunello A; Brazzale A; Sbaraglia M; Dei Tos AP; Baldo V; Benini P; Bortolami A; Rastrelli M; Dall'Olmo L; Rossi CR; Mocellin S
Front Med (Lausanne); 2023; 10():1226090. PubMed ID: 37614947
[TBL] [Abstract][Full Text] [Related]
29. Alterations in Plasma Lipid Profile before and after Surgical Removal of Soft Tissue Sarcoma.
Lee JH; Gwon MR; Kim JI; Hwang SY; Seong SJ; Yoon YR; Kim M; Kim H
Metabolites; 2024 Apr; 14(5):. PubMed ID: 38786727
[TBL] [Abstract][Full Text] [Related]
30. Tumor abnormal protein as a promising biomarker for screening solid malignancies and monitoring recurrence and metastasis.
Zhang Z; Tian C; Liu Y; Zhang L; Sun H; He S; Liu Y; Fan H; Zhang Y; Gao M; Wu S
Front Oncol; 2023; 13():1290791. PubMed ID: 38115905
[TBL] [Abstract][Full Text] [Related]
31. Enhancing Healthcare for Sarcoma Patients: Lessons from a Diagnostic Pathway Efficiency Analysis.
Elyes M; Heesen P; Schelling G; Bode-Lesniewska B; Studer G; Fuchs B;
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835586
[TBL] [Abstract][Full Text] [Related]
32. Curent concepts in pathology of soft tissue sarcoma.
Husain N; Verma N
Indian J Surg Oncol; 2011 Dec; 2(4):302-8. PubMed ID: 23204786
[TBL] [Abstract][Full Text] [Related]
33. Novel metabolomics-biohumoral biomarkers model for predicting survival of metastatic soft-tissue sarcomas.
Vignoli A; Miolo G; Tenori L; Buonadonna A; Lombardi D; Steffan A; Scalone S; Luchinat C; Corona G
iScience; 2023 Oct; 26(10):107678. PubMed ID: 37752948
[TBL] [Abstract][Full Text] [Related]
34. C‑reactive protein and related predictors in soft tissue sarcoma (Review).
Nakamura T; Asanuma K; Hagi T; Sudo A
Mol Clin Oncol; 2024 Jan; 20(1):6. PubMed ID: 38125741
[TBL] [Abstract][Full Text] [Related]
35. Soft Tissue Sarcomas: Treatment and Management.
Miwa S; Wu PK; Tsuchiya H
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473399
[TBL] [Abstract][Full Text] [Related]
36. Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan.
Nakamura T; Asanuma K; Hagi T; Sudo A
Drug Des Devel Ther; 2020; 14():4215-4220. PubMed ID: 33116409
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Significance of Thrombomodulin mRNA in High-Grade Soft Tissue Sarcomas after 10 years.
Asanuma K; Nakamura T; Asanuma Y; Okamoto T; Kakimoto T; Yada Y; Hagi T; Kita K; Nakamura K; Matsumine A; Sudo A
Orthop Surg; 2020 Dec; 12(6):1726-1732. PubMed ID: 33015987
[TBL] [Abstract][Full Text] [Related]
38. Serum thrombomodulin as a metastatic and prognostic marker in soft tissue sarcomas.
Asanuma K; Nakamura T; Asanuma Y; Kakimoto T; Yada Y; Hagi T; Kita K; Matsumine A; Sudo A
Cancer Biomark; 2019; 26(2):163-170. PubMed ID: 31356193
[TBL] [Abstract][Full Text] [Related]
39. Semi-Quantitative Calculations of Primary Tumor Metabolic Activity Using F-18 FDG PET/CT as a Predictor of Survival in 92 Patients With High-Grade Bone or Soft Tissue Sarcoma.
Andersen KF; Fuglo HM; Rasmussen SH; Petersen MM; Loft A
Medicine (Baltimore); 2015 Jul; 94(28):e1142. PubMed ID: 26181552
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
